







an Open Access Journal by MDPI

# **Epigenomics, Epitranscriptomics and Novel Therapy Approaches in Hematology**

Guest Editor:

### Dr. Haiyang Yun

Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

Deadline for manuscript submissions:

closed (15 March 2023)

# **Message from the Guest Editor**

We launch this Special Issue with the aim to gain new insights into the epigenomics and epitranscriptomics in normal and malignant hematopoiesis, and to explore novel therapeutic approaches to treat hematological diseases. In this regard, we encourage the submission of research articles or reviews in the field of clinical or experimental hematology on the following topics: 1) gene mutations or polymorphisms impacting epigenome on epitranscriptome: 2) functional characterization regulators of epigenome or epitranscriptome; 3) clinical evaluation of epigenome or epitranscriptome in patients; 4) animal models to study altered epigenome or epitranscriptome; 5) novel or improved methodological development to quantify the epigenome epitranscriptome; 6) novel gene therapies, gene manipulation, small molecules, or drug synergy with potency to tackle hematological disorders; and 7) clinical trials of novel targeted therapy drugs in hematology.













an Open Access Journal by MDPI

## **Editor-in-Chief**

## Prof. Dr. Selvarangan Ponnazhagan

Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

# Message from the Editor-in-Chief

Genes are central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fastmoving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised.

Why not consider *Genes* for your next genetics paper?

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank: JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))

#### **Contact Us**